Christopher McCabe

PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial

C. Ménard, F. Bénard, M. Brundage, 2022, BMC cancer.

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.

J. Donovan, S. Pinder, H. Earl, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.

A. O'Hagan, A. Sutton, M. Connock, 2006, Health technology assessment.

An evaluation of the clinical and cost-effectiveness of pulmonary artery catheters in patient management in intensive care: a systematic review and a randomised controlled trial.

M. Singer, D. Harrison, D. Young, 2006, Health technology assessment.

Stem cells and beta cell replacement therapy: a prospective health technology assessment study

Christopher McCabe, James M Piret, Klemens Wallner, 2018, BMC Endocrine Disorders.

A prospective randomised comparison of minor surgery in primary and secondary care. The MiSTIC trial.

R. Kneebone, C. McCabe, J. Primrose, 2008, Health technology assessment.

Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.

B. Kiely, D. Rea, B. Naume, 2021 .

Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.

M. Connock, C. McCabe, S. Tubeuf, 2010, Health technology assessment.